featured-image

gorodenkoff/iStock via Getty Images Ligand Pharmaceuticals ( NASDAQ: LGND ) said it will acquire APEIRON Biologics for $100 million in cash. Additionally, the company will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. The firm is also entering into a stock purchase agreement and is committing to invest up to $4 million in invIOs AG, a privately held spin-off of APEIRON.

The deal will be immediately accretive to Ligand’s earnings per share by ~$1.00 on an annualized basis, the firm is also increasing its 2024 revenue guidance to be in the range of $140 million to $157 million, and is raising core adjusted EPS guidance to $5.00 to $5.



50. More on Ligand Pharmaceuticals Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Agenus gains after updating early-stage cancer drug data Ligand Pharmaceuticals Non-GAAP EPS of $1.20 beats by $0.

37, revenue of $30.98M beats by $3.06M.

Back to Health Page